Table 3 Overall and RF-specific associations of estrogen-related polymorphisms and risk of developing erosive disease.

From: Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium

Gene

SNP ID

Effect allele

Overall (n = 816)

RF-positive patients (n = 571)

RF-negative patients (n = 238)

P Interaction

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

CYP1A1

rs1799814

A

0.85 (0.52–1.39)

0.52

0.82 (0.43–1.54)

0.53

0.98 (0.44–2.18)

0.96

0.54

CYP1A2

rs762551

C

0.91 (0.66–1.25)

0.57

0.72 (0.48–1.09)

0.12

1.37 (0.80–2.34)

0.25

0.059

CYP1B1

rs1800440

G

1.06 (0.76–1.46)

0.74

1.12 (0.74–1.69)

0.60

0.97 (0.55–1.69)

0.90

0.50

CYP1B1

rs1056836

G

0.92 (0.64–1.32)

0.66

1.04 (0.67–1.63)

0.85

0.66 (0.34–1.26)

0.21

0.35

CYP1B1

rs10012

G

0.62 (0.37–1.04)§

0.071

0.42 (0.23–0.76)§

0.004

1.70 (0.56–5.17)§

0.35

0.031

CYP2C9

rs1799853

T

0.45 (0.20–1.02)§

0.056

0.16 (0.06–0.46)§

0.0007

2.71 (0.53–13.8)§

0.23

0.003

CYP2C9

rs1057910

C

1.68 (0.98–2.89)

0.059

2.63 (1.15–6.03)

0.012

1.28 (0.58–2.81)

0.54

0.20

CYP2C19

rs12248560

T

1.04 (0.75–1.44)

0.83

1.09 (0.72–1.65)

0.70

0.96 (0.54–1.70)

0.89

0.55

CYP2C19

rs4244285

A

1.00 (0.69–1.44)

0.99

1.02 (0.64–1.61)

0.94

0.90 (0.47–1.70)

0.74

0.79

CYP3A4

rs2740574

G

1.57 (0.90–2.74)

0.11

3.12 (1.29–7.55)

0.004

0.70 (0.29–1.66)

0.42

0.021

CYP3A4

rs11773597

C

1.19 (0.77–1.84)

0.43

1.33 (0.74–2.38)

0.35

1.00 (0.50–2.03)

0.99

0.65

CYP17A1

rs743572

G

0.92 (0.66–1.28)

0.63

0.99 (0.65–1.50)

0.97

0.82 (0.46–1.45)

0.49

0.62

ESR1

rs851984

T

1.07 (0.78–1.46)

0.68

0.82 (0.55–1.24)

0.35

1.56 (0.91–2.68)

0.10

0.078

ESR1

rs2881766

G

1.00 (0.72–1.39)

0.99

1.08 (0.71–1.65)

0.71

0.83 (0.47–1.48)

0.54

0.47

ESR1

rs2071454

G

0.96 (0.65–1.42)

0.82

1.06 (0.65–1.75)

0.81

0.75 (0.38–1.49)

0.42

0.41

ESR1

rs2077647

G

0.92 (0.65–1.30)

0.64

0.70 (0.45–1.09)

0.11

1.46 (0.81–2.63)

0.21

0.030

ESR1

rs827421

C

0.95 (0.67–1.33)

0.75

0.80 (0.52–1.25)

0.33

1.21 (0.66–2.20)

0.54

0.18

ESR1

rs2234693

C

1.10 (0.78–1.55)

0.58

0.97 (0.62–1.51)

0.89

1.33 (0.73–2.40)

0.35

0.32

ESR1

rs9340799

G

0.97 (0.71–1.34)

0.87

0.78 (0.52–1.17)

0.23

1.42 (0.82–2.45)

0.21

0.052

ESR1

rs1801132

G

0.71 (0.52–0.97)

0.034

0.85 (0.57–1.27)

0.44

0.53 (0.31–0.92)

0.025

0.13

ESR1

rs3798577

C

1.21 (0.87–1.68)

0.27

1.39 (0.92–2.10)

0.12

1.12 (0.63–2.01)

0.69

0.50

ESR1

rs910416

T

0.84 (0.59–1.19)

0.33

0.75 (0.47–1.18)

0.21

0.91 (0.51–1.61)

0.74

0.68

ESR2

rs1255998

G

0.92 (0.64–1.33)

0.67

1.07 (0.66–1.72)

0.78

0.72 (0.39–1.34)

0.30

0.44

ESR2

rs928554

G

0.78 (0.52–1.17)§

0.23

0.58 (0.35–0.96)§

0.035

1.39 (0.70–2.78)§

0.35

0.032

ESR2

rs4986938

T

1.09 (0.79–1.51)

0.59

1.41 (0.93–2.11)

0.10

0.74 (0.42–1.29)

0.29

0.068

ESR2

rs1271572

T

0.55 (0.37–0.82)§

0.004

0.38 (0.23–0.63)§

0.0002

1.08 (0.54–2.14)§

0.83

0.018

FcγR2A

rs1801274

G

1.04 (0.72–1.51)

0.82

1.17 (0.74–1.86)

0.50

0.83 (0.43–1.61)

0.58

0.33

FcγR3A

rs396991

C

0.90 (0.64–1.27)

0.56

1.18 (0.76–1.81)

0.46

0.45 (0.24–0.85)

0.013

0.028

GSTP1

rs1695

G

1.05 (0.77–1.44)

0.76

1.16 (0.77–1.75)

0.47

0.70 (0.41–1.21)

0.20

0.26

GSTP1

rs1138272

T

1.32 (0.77–2.25)

0.31

1.70 (0.83–3.46)

0.13

0.71 (0.28–1.77)

0.46

0.24

HSD17B1

rs605059

T

1.12 (0.79–1.59)

0.54

1.24 (0.80–1.92)

0.33

1.12 (0.59–2.12)

0.74

0.82

NR1I2

rs2276706

A

1.01 (0.74–1.40)

0.93

0.96 (0.64–1.43)

0.83

1.18 (0.68–2.06)

0.55

0.47

NR1I2

rs1464603

C

1.16 (0.85–1.59)

0.35

1.14 (0.76–1.69)

0.53

1.45 (0.84–2.49)

0.18

0.54

NR1I2

rs6785049

G

0.92 (0.66–1.27)

0.60

0.95 (0.63–1.43)

0.81

1.03 (0.58–1.84)

0.92

0.93

NR1I2

rs2276707

T

1.03 (0.73–1.45)

0.87

0.80 (0.51–1.23)

0.31

1.62 (0.90–2.89)

0.11

0.064

NR1I2

rs1054191

A

0.83 (0.59–1.17)

0.30

1.02 (0.65–1.58)

0.94

0.58 (0.32–1.06)

0.076

0.12

PGR

rs1042838

A

0.76 (0.53–1.08)

0.13

0.74 (0.47–1.15)

0.18

0.86 (0.46–1.62)

0.64

0.99

PGR

rs1379130

A

0.92 (0.66–1.26)

0.59

1.02 (0.68–1.53)

0.93

0.79 (0.46–1.37)

0.40

0.59

PGR

rs518162

A

1.11 (0.75–1.64)

0.62

1.41 (0.83–2.39)

0.21

0.64 (0.33–1.25)

0.19

0.092

SHBG

rs6259

A

1.22 (0.83–1.78)

0.31

1.87 (1.11–3.14)

0.015

0.66 (0.35–1.23)

0.19

0.006

SULT1A1

rs9282861

A

1.04 (0.76–1.43)

0.79

0.86 (0.58–1.29)

0.46

1.38 (0.80–2.39)

0.25

0.13

  1. Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
  2. Data on RF was available in 809 RA patients. Estimates were adjusted for age, sex and country of origin. P < 0.05 in bold.
  3. Estimates calculated according to a dominant model of inheritance.
  4. §Estimates calculated according to a recessive model of inheritance.